Abstract
AbstractThe global spread of enteric disease, the increasingly limited options for antimicrobial treatment and the need for effective eradication programs have resulted in an increased demand for glycoconjugate enteric vaccines, made with carbohydrate-based membrane components of the pathogen, and their precise characterisation. A set of physico-chemical and immunological tests are employed for complete vaccine characterisation and to ensure their consistency, potency, safety and stability, following the relevant World Health Organization and Pharmacopoeia guidelines. Variable requirements for analytical methods are linked to conjugate structure, carrier protein nature and size and O-acetyl content of polysaccharide. We investigated a key stability-indicating method which measures the percent free saccharide of Salmonella enterica subspecies enterica serovar Typhi capsular polysaccharide, by detergent precipitation, depolymerisation and HPAEC-PAD quantitation. Together with modern computational approaches, a more precise design of glycoconjugates is possible, allowing for improvements in solubility, structural conformation and stability, and immunogenicity of antigens, which may be applicable to a broad spectrum of vaccines. More validation experiments are required to establish the most effective and suitable methods for glycoconjugate analysis to bring uniformity to the existing protocols, although the need for product-specific approaches will apply, especially for the more complex vaccines. An overview of current and emerging analytical approaches for the characterisation of vaccines against Salmonella Typhi and Shigella species is described in this paper. This study should aid the development and licensing of new glycoconjugate vaccines aimed at the prevention of enteric diseases.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Structural Biology,Biophysics
Reference170 articles.
1. Abdelhameed AS, Morris GA, Adams GG, Rowe AJ, Laloux O, Cerny L, Bonnier B, Duvivier P, Conrath K, Lenfant C, Harding SE (2012) An asymmetric and slightly dimerized structure for the tetanus toxoid protein used in glycoconjugate vaccines. Carbohydr Polym 90:1831–1835. https://doi.org/10.1016/j.carbpol.2012.07.032
2. Abdelhameed AS, Adams GG, Morris GA, Almutairi FM, Duvivie P, Conrath K, Harding SE (2016a) A glycoconjugate of Haemophilus influenzae type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate. Sci Rep 6:22208. https://doi.org/10.1038/srep22208
3. Abdelhameed AS, Morris GA, Almutairi F, Adams GG, Duvivier P, Conrath K, Harding SE (2016b) Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein. Sci Rep 6:35588. https://doi.org/10.1038/srep35588
4. Adisinsight.springer.com (2020a) Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma - Adisinsight. https://adisinsight.springer.com/drugs/800048060. Accessed 8 Aug 2020
5. Adisinsight.springer.com (2020b) Typhoid-tetanus toxoid conjugate vaccine - Cadila Healthcare – Adisinsight. https://adisinsight.springer.com/drugs/800047578. Accessed 8 Aug 2020
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献